Tackling the Molecular Profiling Pathway for Lung Cancer

The Welsh Perspective

Dr Craig Dyer

Respiratory Consultant

Welsh Thoracic Oncology Group Lead

Cardiff and Vale UHB

UNITED KINGDOM
LUNG CANCER COALITION

LUNG CANCER LANDSCAPE - WALES



Population



Diagnostics & testing strategies

Treatment Options

LUNG CANCER PATHWAY (2019)



ADVANCEMENT IN THERAPIES



Advances in the treatment of resectable NSCLC

MOLECULAR PROFILING PATHWAY

- Simple to Use / Understand

- Equitable Access

- Communication

OPTIONS APPRAISAL

OPTION 1: DO NOTHING	OPTION 2: SUPPORT IMPLEMENTATION (Cell Pathology Investment)
Advantages - Each HB internally manages limited biomarker testing - No additional spend	**Advantages** - Provide timely lab specimens for NGS - Geographical parity (UK/Europe) - Standardisation - SCP target attainment - Reduction in treatment waits - Reduction in patient anxiety
Disadvantages - Delay to diagnosis - Patients may miss clinically actionable genetic variants - Geographical variation - Staff burn out in Cell Pathology	**Disadvantages** - Increasing cost - Further work for AWMGS to meet KPI

GENETICS WORKSTREAM



LUNG CANCER PATHWAYS (2022)





MOLECULAR SUBPATHWAY (V1)



✓Clear

✓Precise

✓Equitable



SALVAGE PATHWAY (V1)

- ✓Clear
- ✓Understandable

Evaluation of lung RNA NGS service performance by sample type: Biopsies June-August 2022



Evaluation of Cytology service performance by Hospital: Biopsies June-August 2022



MOLECULAR SUBPATHWAY (V2 – Dec 2023)



LESSONS

- Unified approach to requesting

- Sample preparation / handling / salvage

- Transport

- National reporting systems

- Communication

UNITED KINGDOM
LUNG CANCER COALITION

Thank you

Craig.Dyer@wales.nhs.uk

@Lung_Ca_Wales